Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) reported strong financial results for H1 2024, with revenue up 85% and operating expenses down 45%. The company's cash reserves of CHF 15.1 million are expected to fund operations into at least 2026. Key developments include:
1. Anticipated results from the RLF-TD011 trial for epidermolysis bullosa wound treatment
2. Progress in the RLF-OD032 pilot PK study for phenylketonuria, with potential NDA filing by mid- to late 2025
3. Streamlined operations and cost-reduction initiatives
4. Stable R&D investments despite overall expense reduction
The company remains debt-free and expects continued revenue growth to support its development programs.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) ha riportato risultati finanziari eccellenti per il primo semestre del 2024, con un incremento del fatturato dell'85% e una riduzione delle spese operative del 45%. Le riserve di liquidità dell'azienda, pari a CHF 15,1 milioni, dovrebbero finanziare le operazioni almeno fino al 2026. Tra gli sviluppi chiave ci sono:
1. Risultati attesi dal trial RLF-TD011 per il trattamento delle ferite da epidermolisi bollosa
2. Progressi nello studio pilota PK RLF-OD032 per la fenilchetonuria, con possibile deposito NDA entro la metà o la fine del 2025
3. Operazioni semplificate e iniziative di riduzione dei costi
4. Investimenti stabili in R&D nonostante la riduzione complessiva delle spese
L'azienda rimane senza debiti e prevede una continua crescita dei ricavi per supportare i suoi programmi di sviluppo.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) informó resultados financieros sólidos para el primer semestre de 2024, con un aumento del 85% en los ingresos y una disminución del 45% en los gastos operativos. Las reservas de efectivo de la compañía, de CHF 15.1 millones, se espera que financien las operaciones hasta al menos 2026. Los desarrollos clave incluyen:
1. Resultados anticipados del ensayo RLF-TD011 para el tratamiento de heridas por epidermólisis bullosa
2. Avances en el estudio piloto PK RLF-OD032 para la fenilcetonuria, con posible presentación de NDA a mediados o finales de 2025
3. Operaciones optimizadas e iniciativas de reducción de costos
4. Inversiones estables en I+D a pesar de la reducción general de gastos
La empresa se mantiene libre de deudas y espera un crecimiento continuo de los ingresos para respaldar sus programas de desarrollo.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY)는 2024년 상반기에 강력한 재무 결과를 보고했습니다. 매출이 85% 증가하고 운영 비용이 45% 감소했습니다. 회사의 현금 보유액인 CHF 15.1 백만은 최소 2026년까지 운영을 지원할 것으로 예상됩니다. 주요 발전 사항은 다음과 같습니다:
1. 피부에 수포가 생기는 질환(표피 박리증) 치료를 위한 RLF-TD011 임상시험의 예상 결과
2. 페닐케톤뇨증을 위한 RLF-OD032 파일럿 약리학적 연구의 진전, 2025년 중반에서 말까지 NDA 제출 가능성
3. 효율적인 운영 및 비용 절감 이니셔티브
4. 전체 비용 감소에도 불구하고 안정적인 연구개발 투자
회사는 부채가 없으며, 개발 프로그램을 지원하기 위해 지속적인 매출 성장을 기대하고 있습니다.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) a annoncé de solides résultats financiers pour le premier semestre de 2024, avec une augmentation de 85% des revenus et une réduction de 45% des dépenses d'exploitation. Les réserves de trésorerie de l'entreprise, s'élevant à CHF 15,1 millions, devraient financer les opérations jusqu'à au moins 2026. Les développements clés incluent :
1. Résultats anticipés de l'essai RLF-TD011 pour le traitement des plaies dû à l'épidermolyse bulleuse
2. Progrès dans l'étude pilote PK RLF-OD032 pour la phénylcétonurie, avec un dépôt potentiel du NDA d'ici la mi-fin 2025
3. Opérations rationalisées et initiatives de réduction des coûts
4. Investissements en R&D stables malgré une réduction globale des dépenses
L'entreprise reste sans dettes et s'attend à une croissance continue des revenus pour soutenir ses programmes de développement.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, OTCQB:RLFTY) hat für das erste Halbjahr 2024 starke finanzielle Ergebnisse gemeldet, mit einem Umsatzanstieg von 85% und einer Reduzierung der Betriebskosten um 45%. Die liquiden Mittel des Unternehmens in Höhe von CHF 15,1 Millionen werden voraussichtlich die Geschäftstätigkeiten bis mindestens 2026 finanzieren. Zu den wichtigen Entwicklungen gehören:
1. Erwartete Ergebnisse der RLF-TD011-Studie zur Behandlung von Wunden bei Epidermolysis bullosa
2. Fortschritte in der Pilotstudie zur Pharmakokinetik RLF-OD032 für Phenylketonurie, mit möglicher NDA-Einreichung bis Mitte oder Ende 2025
3. Optimierte Abläufe und Kostenreduktionsinitiativen
4. Stabile Investitionen in F&E trotz allgemeiner Kostensenkung
Das Unternehmen bleibt schuldenfrei und erwartet ein fortgesetztes Umsatzwachstum zur Unterstützung seiner Entwicklungsprogramme.
- Revenue increased by 85% in H1 2024
- Operating expenses reduced by 45%
- Cash reserves of CHF 15.1 million expected to fund operations into at least 2026
- Company remains debt-free
- Stable R&D investments despite overall expense reduction
- None.
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks
RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025
Streamlined operations and CHF 15.1 million cash reserves expected to provide funding into at least 2026
GENEVA, SWITZERLAND / ACCESSWIRE / August 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported its financial results for the half-year ended June 30, 2024, and provided a corporate update.
Relief provided updates on its key development programs and strategic initiatives, including RLF-TD011, a hypochlorous acid topical spray designed for the treatment of epidermolysis bullosa (EB), and RLF-OD032, a novel liquid formulation of sapropterin dihydrochloride for the management of phenylketonuria (PKU).
The Company reported significant financial improvements in the first half of 2024, with revenue up
The Relief 2024 half-year report is available on the Company's website.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
SOURCE: Relief Therapeutics Holdings AG
View the original press release on accesswire.com
FAQ
What were Relief Therapeutics' (RLFTY) financial results for H1 2024?
When are the results for Relief Therapeutics' RLF-TD011 trial for epidermolysis bullosa expected?
What is the timeline for Relief Therapeutics' (RLFTY) potential NDA filing for RLF-OD032?
How long is Relief Therapeutics' (RLFTY) current cash expected to last?
